Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study

Mayo Clinic Proceedings

Volumn 77, Issue 10, 2002, Pages 1044-1052

  Greenspan, Susan ^a   Field Munves, Ellen ^b   Tonino, Richard ^c   Smith, Mary ^d   Petruschke, Richard ^d   Wang, Lixia ^d   Yates, John ^d   De Papp, Anne E ^d   Palmisano, Joanne ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Gateway Professional Center   (United States)

^c Good Health   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DUODENUM ULCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLATULENCE; GASTRITIS; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE LEVEL;

EID: 0036787508     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.10.1044     Document Type: Article

References (31)

1. Liberman UA, Weiss SR, Broll J, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
2. Black DM, Cummings SR, Karpf DB, et al, Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
4. Pols HA, Felsenberg D, Hanley DA, et al, Foxamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9:461-468.
5. Black DM, Thompson DE, Bauer DC, et al, FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [published correction appears in J Clin Endocrinol Metab. 2001;86:938]. J Clin Endocrinol Metab. 2000;85:4118-4124.
6. Saag KG, Emkey R, Schnitzer TJ, et al, Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
7. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000;22:15-28.
8. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract. 1999;101(suppl):51-61.
9. Mersfelder T, Armitstead JA, Ivey MF, Cedars M. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q. 1999;18:50-58.
10. Palmisano J, Lewiecki EM, Rosen C, et al. Preference study of alendronate 70 mg once-weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. In: Program and abstracts of the Fifth International Symposium: Clinical Advances in Osteoporosis; March 6-9, 2002; Honolulu, Hawaii. Abstract 100.
11. Kleerekoper M, Schein JR. Comparative safety of bone remodeling agents with a focus on osteoporosis therapies. J Clin Pharmacol. 2001;41:239-250.
12. Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001;27:197-214.
13. Greenspan SL, Harris ST, Bone H, et al. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician. 2000;61:2731-2736.
14. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf. 1996;14:158-170.
15. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med. 2000;160:517-525.
16. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
17. Lanza FL, Hunt RH, Thompson AB, Provenza JM, Blank MA, Risedronate Endoscopy Study Group. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000;119:631-638.
18. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol. 2000;95:634-640.
19. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002;97:58-64.
20. Schnitzer T, Bone HG, Crepaldi G, et al, Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano). 2000;12:1-12.
21. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42:175-195.
22. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. Chichester, England: John Wiley & Sons; 1996.
23. Taxel P. Osteoporosis: detection, prevention, and treatment in primary care. Geriatrics. 1998;53:22-23, 27-28, 33.
24. South-Paul JE. Osteoporosis, part I: evaluation and assessment. Am Fam Physician. 2001;63:897-904.
25. Cymet TC, Wood B, Orbach N. Osteoporosis. J Am Osteopath Assoc. 2000;100(10 su pt 1):S9-S15.
26. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1-45.
27. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis [published correction appears in N Engl J Med. 1993;328:65]. N Engl J Med. 1992;327:620-627.
28. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
29. Rizzoli R, Greenspan SL, Bone HG, et al. Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. In press.
30. National Prescription Audit Plus™ and National Disease and Therapeutic Index™, Fosamax Total Prescriptions, January 2001 December 2001. IMS HEALTH, Plymouth Meeting, Pa. Available at: www.imshealth.com/. Accessibility verified September 9, 2002.
31. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.